Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
about
Towards tumor immunodiagnosticsCheckpoint Inhibitors and Their Application in Breast CancerTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingNeoadjuvant nab-paclitaxel in the treatment of breast cancerManaging breast cancer in younger women: challenges and solutionsCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateTriple negative breast cancer: looking for the missing link between biology and treatmentsRelevance of tumor-infiltrating lymphocytes in breast cancerVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerTherapeutic Lymphoid Organogenesis in the Tumor MicroenvironmentThe Right Treatment for the Right Patient – Personalised Treatment of Breast CancerBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinomaNovel therapeutic strategies for patients with triple-negative breast cancerPossible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responsesTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cellsTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Precision medicine in breast cancer: reality or utopia?The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationTriple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceBreast Cancer Update 2014 - Focus on the Patient and the Tumour.Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
P2860
Q26738691-2DC7ED46-DE0B-4371-B2C8-EC096A6F6C85Q26745442-554662B9-DCAD-4938-8260-DE291C1907DFQ26745446-6B38194F-D312-457D-89D8-BEA757ADAF75Q26747695-41D3446F-C408-4B4E-9969-ECA5CCDD75BAQ26747792-A2AE733D-F55A-4630-84DC-DDA6E47A235CQ26748822-A35E75A1-47DA-46D0-9723-4D3A045AB662Q26771184-E5091A08-A502-4D43-89E8-DA972B1C5BC9Q26782573-A057082E-8513-47EB-B40E-D7BAFA3D008EQ26783122-7D49D5A5-EBE8-4638-A936-6BABC14F4ADEQ26795598-6B7ACE86-2E3C-4854-AB71-ECD52344F68FQ26796314-36E59C6C-4DC5-426E-8279-73CAB0796DCAQ26798074-197E3A36-35DA-4930-932F-3729E136D985Q26799123-BBF8A1A5-1215-4D77-9274-1AC393F90DEEQ26800260-F9DB7252-1780-4906-B192-562EB4443BD4Q27311085-A060FC3A-BEAA-4576-9650-C63FBE290875Q27853285-AC34726B-46E4-4F0A-ABB5-F20A95957EBDQ28067436-5FB4B6BA-B663-479C-9174-1262DA70EBB1Q28068802-FE7E4FF0-056E-4117-9457-5E4419025852Q28085062-D3FA4EB5-260C-4DA9-9375-51621FE01635Q28554412-229C7DB6-1FF4-4B45-BD4E-A97C39533459Q30253017-5A6117C9-585A-4D84-9D23-F319F07A6189Q30315970-83A132BA-09AA-4F37-8869-8BAFBFAA3450Q30316383-29F900BD-D6D0-460B-B972-792961823C4DQ33441772-ACBF7773-C85C-40FA-BAB5-36C5A5D0B920Q33751184-A0F8A046-E555-4B8C-8E78-2EB41B57C80CQ33769821-7D7D5355-02F7-4C78-B9F2-7CB9595C1814Q33809114-FE651C70-4E56-4F03-B328-AA4E66E8AD2AQ33886353-AB211894-F43C-413B-97B3-21F7DCBBEF69Q33887682-EEAE1934-8B82-4F32-9617-467CB7E4F705Q33915040-25103491-A763-4753-91FE-CA33D6EC4726Q33915044-A12913B1-83EB-49B9-8955-DCA392B1B41CQ33915057-E51C8B6E-DFD6-49A7-886A-21C1F6620F71Q34476337-A863C684-FE76-4FFA-806F-AF8AB7343663Q34512092-F636465F-C272-4891-8D12-FACB09E0D0AEQ35180940-1FA26767-AFFB-4038-9B39-EAB3518B758AQ35496344-C6750493-3C7A-4ED9-9AED-2C2AD9F2652EQ35870134-B119D517-5674-4293-9AEE-89770EA89DD0Q35933373-CA0F2AC3-A330-405F-8188-F91964681351Q35955369-6C03D4CC-F7ED-4EBF-96E4-99BE35DE3C48Q35992815-CFF31603-A883-486C-A80E-16CD217F8142
P2860
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@en
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@nl
type
label
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@en
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@nl
prefLabel
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@en
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@nl
P2093
P50
P356
P1476
Tumor-infiltrating lymphocytes ...... gative primary breast cancers.
@en
P2093
Berit M Pfitzner
Bruno V Sinn
Christian Jackisch
Christian Schem
Christoph Salat
Christos Sotiriou
Fabrice André
Frederick Klauschen
Gunter von Minckwitz
Hans Tesch
P304
P356
10.1200/JCO.2014.58.1967
P407
P50
P577
2014-12-22T00:00:00Z